Defining valuable information in a shifting industry

Issue  JCB, Volume 19, Number 2, 2013  Commentary 

Andrew F Bourgoin
Thomson Reuters

DOI:https://doi.org/10.5912/jcb606


Abstract:

Keywords:pharmaceuticals ,biologics ,generics ,biosimilars ,en ,

Download PDF